{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:02:03Z","timestamp":1790996523491,"version":"4.1.0"},"reference-count":38,"publisher":"BMJ","issue":"9","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["DTB"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:p>Over the past two decades, considerable data have emerged on an association between drugs with anticholinergic activity and serious adverse effects in older people. Well-recognised anticholinergic adverse effects include dry mouth, blurred vision, constipation and urinary retention. Of particular concern is the potential impact on cognitive function with several studies showing that long-term use of medicines with anticholinergic activity is associated with worsening of cognitive function, increased incidence of dementia and increased mortality. This article gives an overview of the evidence, discusses some of the tools used to identify high-risk drugs and highlights issues to consider when prescribing drugs with anticholinergic activity with a view to reducing potential risks in older people and those at highest risk of cognitive impairment.<\/jats:p>","DOI":"10.1136\/dtb.2022.000066","type":"journal-article","created":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T05:05:15Z","timestamp":1693371915000},"page":"135-139","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":15,"title":["Managing drugs with anticholinergic activity"],"prefix":"10.1136","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6254-2054","authenticated-orcid":false,"given":"Delia","family":"Bishara","sequence":"first","affiliation":[{"name":"Mental Health of Older Adults and Dementia, South London and Maudsley NHS Foundation Trust, London, UK"},{"name":"Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King\u2019s College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,8,30]]},"reference":[{"key":"2025082623214226000_61.9.135.1","unstructured":"World Health Organization . Dementia [online]. 2023. Available: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dementia [Accessed 04 Jul 2023]."},{"key":"2025082623214226000_61.9.135.2","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1001\/jamainternmed.2019.0677","article-title":"Anticholinergic drug exposure and the risk of dementia: a nested case-control study","volume":"179","author":"Coupland","year":"2019","journal-title":"JAMA Intern Med"},{"key":"2025082623214226000_61.9.135.3","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.k1315","article-title":"Anticholinergic drugs and risk of dementia: case-control study","volume":"361","author":"Richardson","year":"2018","journal-title":"BMJ"},{"key":"2025082623214226000_61.9.135.4","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/jamainternmed.2014.7663","article-title":"Cumulative use of strong Anticholinergics and incident dementia: a prospective cohort study","volume":"175","author":"Gray","year":"2015","journal-title":"JAMA Intern Med"},{"key":"2025082623214226000_61.9.135.5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2011.03491.x"},{"key":"2025082623214226000_61.9.135.6","doi-asserted-by":"crossref","DOI":"10.1186\/s12877-020-01657-x","article-title":"Increasing prevalence of anticholinergic medication use in older people in England over 20 years: cognitive function and ageing study I and II","volume":"20","author":"Grossi","year":"2020","journal-title":"BMC Geriatr"},{"key":"2025082623214226000_61.9.135.7","article-title":"Anticholinergic drugs and dementia: time for transparency in the face of uncertainty","volume":"9","author":"Woodford","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"2025082623214226000_61.9.135.8","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.neubiorev.2021.04.031","article-title":"Anticholinergic drugs and the risk of dementia: a systematic review and meta-analysis","volume":"127","author":"Zheng","year":"2021","journal-title":"Neurosci Biobehav Rev"},{"key":"2025082623214226000_61.9.135.9","unstructured":"National Institute for Health and Care Excellence . Clinical knowledge summaries \u2013 dementia [online]. 2022. Available: https:\/\/cks.nice.org.uk\/topics\/dementia\/ [Accessed 04 Jul 2023]."},{"key":"2025082623214226000_61.9.135.10","doi-asserted-by":"crossref","DOI":"10.1002\/trc2.12290","article-title":"Association between anticholinergic burden and dementia in UK Biobank","volume":"8","author":"Mur","year":"2022","journal-title":"Alzheimers Dement (N Y)"},{"key":"2025082623214226000_61.9.135.11","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-199303040-00004"},{"key":"2025082623214226000_61.9.135.12","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajgp.11.4.458"},{"key":"2025082623214226000_61.9.135.13","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1016\/j.jamda.2021.08.011","article-title":"Centrally acting anticholinergic drugs used for urinary conditions associated with worse outcomes in dementia","volume":"22","author":"Bishara","year":"2021","journal-title":"J Am Med Dir Assoc"},{"key":"2025082623214226000_61.9.135.14","doi-asserted-by":"publisher","DOI":"10.2165\/11597530-000000000-00000"},{"key":"2025082623214226000_61.9.135.15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2005.00537.x"},{"key":"2025082623214226000_61.9.135.16","first-page":"490","article-title":"Re: anticholinergic drug use, serum anticholinergic activity, and adverse drug events among older people: a population-based study","volume":"192","author":"Griebling","year":"2014","journal-title":"J Urol"},{"key":"2025082623214226000_61.9.135.17","doi-asserted-by":"crossref","first-page":"105041","DOI":"10.1016\/j.archger.2023.105041","article-title":"Frequency and clinical impact of anticholinergic burden in older patients: comparing older patients with and without chronic kidney disease","volume":"112","author":"Yildiz","year":"2023","journal-title":"Arch Gerontol Geriatr"},{"key":"2025082623214226000_61.9.135.18","doi-asserted-by":"crossref","DOI":"10.3390\/geriatrics5040085","article-title":"Multi-morbidity and polypharmacy in older people: challenges and opportunities for clinical practice","volume":"5","author":"Aggarwal","year":"2020","journal-title":"Geriatrics (Basel)"},{"key":"2025082623214226000_61.9.135.19","doi-asserted-by":"publisher","DOI":"10.2217\/1745509X.4.3.311"},{"key":"2025082623214226000_61.9.135.20","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-013-1499-3"},{"key":"2025082623214226000_61.9.135.21","doi-asserted-by":"crossref","DOI":"10.1186\/s12877-015-0029-9","article-title":"Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review","volume":"15","author":"Salahudeen","year":"2015","journal-title":"BMC Geriatr"},{"key":"2025082623214226000_61.9.135.22","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.12263"},{"key":"2025082623214226000_61.9.135.23","article-title":"Staff awareness of anti-cholinergic burden (ACB) - a qualitative cross-sectional study in a tertiary care hospital","volume":"13","author":"Soundararajan","year":"2021","journal-title":"Cureus"},{"key":"2025082623214226000_61.9.135.24","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/gps.4507","article-title":"Anticholinergic effect on cognition (AEC) of drugs commonly used in older people","volume":"32","author":"Bishara","year":"2017","journal-title":"Int J Geriatr Psychiatry"},{"key":"2025082623214226000_61.9.135.25","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/gps.5330","article-title":"The anticholinergic effect on cognition (AEC) scale\u2014associations with mortality, hospitalisation and cognitive decline following dementia diagnosis","volume":"35","author":"Bishara","year":"2020","journal-title":"Int J Geriatr Psychiatry"},{"key":"2025082623214226000_61.9.135.26","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1192\/bjb.2019.43","article-title":"Safe prescribing in cognitively vulnerable patients: the use of the anticholinergic effect on cognition (AEC) tool in older adult mental health services","volume":"44","author":"Bishara","year":"2019","journal-title":"BJPsych Bull"},{"key":"2025082623214226000_61.9.135.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2020.05.037"},{"key":"2025082623214226000_61.9.135.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2009.02.021"},{"key":"2025082623214226000_61.9.135.29","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006292126"},{"key":"2025082623214226000_61.9.135.30","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2007.106"},{"key":"2025082623214226000_61.9.135.31","doi-asserted-by":"publisher","DOI":"10.1370\/afm.2501"},{"key":"2025082623214226000_61.9.135.32","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00228-020-02994-x","article-title":"Quality of anticholinergic burden scales and their impact on clinical outcomes: a systematic review","volume":"77","author":"Lisibach","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"key":"2025082623214226000_61.9.135.33","unstructured":"National Institute for Health and Care Excellence . Dementia: assessment, management and support for people living with dementia and their carers (NG97) [online]. 2018. Available: https:\/\/www.nice.org.uk\/guidance\/ng97 [Accessed 04 Jul 2023]."},{"key":"2025082623214226000_61.9.135.34","unstructured":"Burns A , Twomey P , Barrett E , et al . Dementia diagnosis and management: a brief pragmatic resource for general practitioners [online]. 2015. Available: https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2015\/01\/dementia-diag-mng-ab-pt.pdf [Accessed 04 Jul 2023]."},{"key":"2025082623214226000_61.9.135.35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2012.03922.x"},{"key":"2025082623214226000_61.9.135.36","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.793","article-title":"Anticholinergic drugs and risk of dementia: time for action","volume":"9","author":"Bell","year":"2021","journal-title":"Pharmacol Res Perspect"},{"key":"2025082623214226000_61.9.135.37","doi-asserted-by":"crossref","DOI":"10.1186\/s12888-019-2055-1","article-title":"A case report of cholinergic rebound syndrome following abrupt low-dose clozapine discontinuation in a patient with type I bipolar affective disorder","volume":"19","author":"Galova","year":"2019","journal-title":"BMC Psychiatry"},{"key":"2025082623214226000_61.9.135.38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/gps.5722","article-title":"A systematic review of interventions to reduce anticholinergic burden in older people with dementia in primary care","volume":"37","author":"Shawaqfeh","year":"2022","journal-title":"Int J Geriatr Psychiatry"}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2022.000066","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T06:21:58Z","timestamp":1756275718000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2022.000066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,30]]},"references-count":38,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,8,30]]},"published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1136\/dtb.2022.000066"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2022.000066","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"value":"0012-6543","type":"print"},{"value":"1755-5248","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,30]]}}}